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The Use of Recombinant Tissue Plasminogen Activator (rTPA) in
The Treatment of Fibrinous Pleuropneumonia in Horses: 25 Cases
(2007–2012)
J.E. Tomlinson, E. Byrne, N. Pusterla, K. Gary Magdesian, H.G. Hilton, B. McGorum, E. Davis,
A. Schoster, L. Arroyo, B. Dunkel, H. Carslake, R.C. Boston, and A.L. Johnson
Background: Information about treatment protocols, adverse eﬀects and outcomes with intrapleural recombinant tissue
plasminogen activator (rTPA) use in horses with ﬁbrinous pleuropneumonia is limited.
Hypothesis/Objectives: Describe factors that contribute to clinical response and survival of horses treated with rTPA
intrapleurally.
Animals: Horses with bacterial pneumonia and ﬁbrinous pleural eﬀusion diagnosed by ultrasonography, that were treated
with rTPA intrapleurally.
Methods: Retrospective multicenter case series from 2007–2012. Signalment, history, clinical and laboratory evaluation, treatment,
and outcome obtained from medical records. Regression analysis used to identify associations between treatments and outcomes.
Results: Thirty three hemithoraces were treated in 25 horses, with 55 separate treatments. Recombinant tissue plasmino-
gen activator (375–20,000 lg/hemithorax) was administered 1–4 times. Sonographically visible reduction in ﬁbrin mat thick-
ness, loculations, ﬂuid depth, or some combination of these was seen in 32/49 (65%) treatments. Response to at least 1
treatment was seen in 17/20 (85%) horses with sonographic follow-up evaluation after every treatment. Earlier onset of rTPA
treatment associated with increased survival odds. No association was found between cumulative rTPA dose or number of
rTPA doses and survival, development of complications, duration of hospitalization or total charges. Clinical evidence of
hypocoagulability or bleeding was not observed. Eighteen horses (72%) survived to discharge.
Conclusions and clinical importance: Treatment with rTPA appeared safe and resulted in variable changes in ﬁbrin quan-
tity and organization within the pleural space. Recombinant tissue plasminogen activator could be a useful adjunct to stan-
dard treatment of ﬁbrinous pleuropneumonia, but optimal case selection and dosing regimen remain to be elucidated.
Key words: intrapleural; ﬁbrinolysis; alteplase; pleuritis.
P leural ﬁbrin deposition is a common occurrence inparapneumonic eﬀusions in horses. In a recent ret-
rospective study, it aﬀected 85% of horses with
bacterial pleuropneumonia, and was associated with
decreased survival.1 Fibrin loculations create separated
ﬂuid pockets that inhibit thorough drainage of the pleu-
ral cavity and likely impair antimicrobial penetration.2–4
Repeated drainage and monitoring of pleural eﬀusions
are major causes of morbidity and expense in the treat-
ment of pleuropneumonia in horses and can aﬀect dura-
tion of hospitalization. Consequently, there is a strong
interest in developing methods to prevent, decrease or
remove ﬁbrin deposits. Thoracoscopy has been advo-
cated as a procedure to break down ﬁbrinous locula-
tions early in the disease process,5 but it has not gained
widespread use. This likely is because of the limited
ﬁeld of view obtained, the surgical and anesthetic exper-
tise required, potential complications, and the likelihood
of reformation of ﬁbrinous adhesions after the proce-
dure.5 Standing thoracotomy is another option for
removal of pleural ﬁbrin, and it has been reported to
result in a high survival rate of 88%.6 This procedure,
however, often is reserved for end-stage disease, after
pleural abscess formation, so that the abscess capsule
prevents development of iatrogenic pneumothorax. The
procedure also is associated with a high rate of compli-
cations (50%), surgical pain, and a prolonged recovery
time with a median of 2.5 months for incisional heal-
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ing.6 In search of a less invasive procedure, there has
been increasing interest in intrapleural ﬁbrinolytic treat-
ment (IPFT) to break down ﬁbrin loculations and
improve drainage. The goals of IPFT are decreased hos-
pitalization time because of faster resolution of pleural
eﬀusion, decreased incidence of complications such as
pleural abscesses, decreased need for surgical interven-
tion, and improved survival rate. We report the use of
IPFT in 25 horses with ﬁbrinous bacterial pleuropneu-
monia and investigate treatment factors that might
aﬀect outcome.
Materials and methods
Participating institutions were identiﬁed by contacting diplo-
mates of the American College of Veterinary Internal Medicine
and the European College of Equine Internal Medicine who spe-
cialize in large animal medicine using the listserve. Inclusion criteria
were diagnosis of bacterial pleuropneumonia by clinical examina-
tion and culture, ﬁbrinous pleural eﬀusion on thoracic sonography,
and treatment with intrapleural recombinant tissue plasminogen
activator (rTPA) at least once. Investigators contributed all such
cases treated at their respective hospitals over the study period.
Historical information collected from the medical records
included age, sex, breed, and duration of clinical signs before hos-
pitalization. Details obtained regarding clinical examination at
admission were the presence or absence of fever, cough, nasal dis-
charge, malodorous breath or nasal discharge, tachypnea, pleuro-
dynia, abnormal mucous membranes, and thoracic auscultation
ﬁndings. Admission peripheral blood leukocyte and platelet counts
and plasma ﬁbrinogen concentration were recorded. Additional
information included duration of hospitalization, total inpatient
charges, cost of rTPA, bacterial isolates from tracheal ﬂuid, pleu-
ral ﬂuid, or both, medications used, adjunctive therapies, compli-
cations, and outcome.
Details speciﬁc to pleural ﬂuid drainage and rTPA administra-
tion were collected separately for each hemithorax and included
number of drains placed, initial volume drained, ﬂuid nucleated
cell count, ﬂuid protein concentration, odor of ﬂuid obtained,
duration of drainage, timing and number of treatments, dose of
rTPA used, and sonographic appearance before and after each
rTPA treatment. The sonographic response to treatment was sub-
jectively described by each attending clinician and categorized as
improved, mildly improved, not improved/worsened. The mildly
improved description was thought to be more open to bias because
treatment was not blinded and therefore this category was com-
bined with the not improved/worsened category for analysis to
provide the most conservative estimate of the results of treatment.
To be categorized as improved, at least 1 of the following was pre-
sent: clear reduction in maximal ﬂuid height, breakdown of locula-
tions, or reduction in total amount of ﬁbrin.
Statistical analysis
Data were summarized using descriptive statistics. The median
and range were reported.
Factors that could aﬀect survival were investigated using logis-
tic regression. The primary exposures of interest were the cumula-
tive dosage of rTPA, total number of rTPA treatments, and the
day of hospitalization on which the ﬁrst rTPA treatment was
administered. For this purpose, the day of treatment was natural
log transformed to decrease the eﬀect of right skew. The following
confounders were considered: which hemithorax was treated, bac-
teriologic agents, anaerobic infection, malodorous breath or pleu-
ral ﬂuid, epistaxis, use of hyperbaric oxygen treatment, age, total
volume of pleural ﬂuid drained at ﬁrst thoracocentesis, peripheral
blood leukocyte counts and ﬁbrinogen concentrations at admis-
sion, and duration of clinical disease before admission.
Exposures that could aﬀect the change in sonographic appear-
ance after rTPA administration were investigated using logistic
regression. Exposures included the variables described above as
well as the dose number (1st – 4th dose), day of hospitalization on
which rTPA was administered, individual dose of rTPA, and dura-
tion that drains were clamped after rTPA administration. For this
purpose, sonographic outcome was collapsed into 2 categories:
improved, or mild improvement/no change/deterioration.
Robust regression analysis was used to determine the associa-
tion of cumulative dosage of rTPA and number of treatments with
rTPA with the following outcomes: number of indwelling thoracic
drains used, duration of thoracic drainage, occurrence of compli-
cations, occurrence of pleural abscessation, treatment with thora-
cotomy, duration of hospitalization, and total charges.
Fisher’s exact test was used to compare survival and complica-
tion rates from this study with those reported for horses with ﬁbri-
nous pleuropneumonia that were not treated with IPFT.1
Commercial statistical software was useda and signiﬁcance was
set at P < 0.05.
Results
Records of 25 horses from 8 clinics were obtained for
analysis. One of these cases was included in a previous
publication.7 They included 13 (52%) females, 5 (20%)
intact males, and 7 (28%) geldings. The median age
was 3 years (range, 14 days – 19 years). The breeds
were 12 (48%) Thoroughbred, 4 (16%) Quarter Horse,
4 (16%) Warmblood, 2 (8%) Irish Sport Horse, and 1
(4%) each Standardbred, Thoroughbred cross and Paint
Horse.
The median duration of clinical signs before presenta-
tion was 4.5 days (range, 0 h [developed in hospital]—
21 days).
Clinical signs at presentation included fever (n = 11),
cough (13), nasal discharge (13) that was sanguineous
in 5 horses and malodorous in 10, tachypnea (18), pleu-
rodynia (12), and abnormal mucous membranes (9).
Lung sounds were decreased ventrally in 20 horses, and
5 horses had crackles, wheezes, pleural friction rubs, or
some combination of these. Median peripheral blood
leukocyte count at admission was 9.63 9 109 cells/L
(range, 2.7–34.2 9 109 cells/L). Median ﬁbrinogen con-
centration at admission was 6 g/L (range, 2.95–10.84 g/
L). Median blood platelet count was 150 9 109/L
(range, 94–300 9 109/L).
Aerobic infection was conﬁrmed in 23 horses;
anaerobic in 13 and combined aerobic and anaerobic
infection in 12 (Table 1). Of 19 tracheal aspirates, 18
were positive on aerobic and 10 were positive on
anaerobic culture. Of 22 pleural ﬂuid samples, 18 were
positive on aerobic and 10 were positive on anaerobic
culture. Polymicrobial infections were common, with
only 4 horses having only a single bacterial species
cultured. The most common isolate was Streptococcus
equi sbsp. zooepidemicus (19). The 2 most common
anaerobic isolates were Fusobacterium necrophorum (6),
and Prevotella spp. (6). A single neonate had blood
and nasal swab cultures instead of transtracheal aspi-
rate culture because of its small size. These cultures
yielded a coagulase negative Staphylococcus and
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Bordetella bronchiseptica, respectively. In all cases, the
isolated bacteria were sensitive to the antimicrobials
being utilized for treatment.
Horses received treatment at the clinicians’ discretion
(Table 2). Antimicrobials were used in combination and
frequently were changed from the IV to PO route of
administration during hospitalization.
Initial treatment consisted of placement of indwelling
thoracic drains in 1 or both hemithoraces or intermittent
drainage with a teat cannula. The median initial volume
of pleural ﬂuid drained from each side was 2 liters
(range, 0–32 L). A median of 2 drains were placed per
horse during hospitalization, 1 drain per hemithorax
(range, 0–17 drains) for a median duration of drainage
of 10 days (range, 0–150 days). The reasons for remov-
ing or replacing drains included blockage of the drain,
insertion site cellulitis, or resolution of eﬀusion.
Primary reasons cited for treatment with rTPA were
to decrease loculations that were perceived to impede
drainage of pleural ﬂuid, lysis of adhesions, and to pre-
vent pleural abscessation. Repeated obstruction of the
indwelling drains with ﬁbrin was not cited as a reason
for IPFT. The ﬁnancial resources of the owner often
were a deciding factor in whether to implement IPFT.
Recombinant tissue plasminogen activator treatment
rarely was initiated on the ﬁrst day of treatment
(median, day 4; range, day 1–76) and never on the ﬁrst
day of clinical signs (median, day 9.5; range, day 4–77).
All horses received alteplase and none received a
DNase. The median number of rTPA doses per horse
Table 1. Combined culture results for tracheal aspi-
rates and pleural ﬂuid from 24 horses with ﬁbrinous
pleuropneumonia that were subsequently treated with
intrapleural ﬁbrinolytic treatment. FA, facultatively
anaerobic
Aerobic and
FA isolates (n = 38)
No. horses
from which
isolate was
cultured (%)
Obligate
anaerobic
isolates
(n = 26)
No. horses
from which
isolate was
cultured
(%)
Gram + cocci Gram + cocci
Streptococcus equi
sbsp zooepidemicus
19 (76) Peptostreptococcus
spp.
3 (12)
Staphylococcus
aureus
1 (4)
Group C beta
hemolytic
Streptococcus,
not speciated
1 (4) Gram + bacilli
unidentiﬁed 1 (4)
Enterococcus spp. 1 (4)
Rhodococcus equi 1 (4)
Gram - bacilli Gram - bacilli
Escherichia coli 6 (24) Fusobacterium
necrophorum
6 (24)
Actinobacillus equuli 3 (12) Prevotella spp. 6 (24)
Pasteurella spp. 2 (8) Porphyromonas
spp.
4 (16)
Enterobacter spp. 2 (8) Bacteroides spp. 4 (16)
Morganella morganii 1 (4) unidentiﬁed 2 (8)
Klebsiella spp. 1 (4)
Total no. horses with
aerobic/FA isolates
23 (92) Total no. horses
with anaerobic
isolates
13 (52)
Table 2. Treatments administered to 25 horses with
ﬁbrinous pleuropneumonia that were also administered
intrapleural ﬁbrinolytic treatment
Antimicrobial
treatment
No. horses
treated (%)
Adjunctive
treatment
No. horses
treated (%)
Aminoglycoside NSAID 24 (96)
Gentamicin 22 (88) Flunixin
meglumine
23 (92)
Amikacin 1 (4) Phenylbutazone 6 (24)
Meloxicam 2 (8)
Beta lactam Aspirin 2 (8)
Penicillin 12 (48) Diclofenac 2%
topical cream
2 (8)
Ampicillin 3 (12)
Ceftiofur 9 (36) Gastrointestinal
health support
12 (48)
Cefquinome 2 (8) Probiotic bacteria 10 (40)
Biosponge 9 (36)
Metronidazole 17 (68) Omeprazole 8 (32)
Ranitidine 3 (12)
Potentiated sulfa 9 (36) Bismuth
subsalicylate
2 (8)
Sucralfate 2 (8)
Fluoroquinolone
Enroﬂoxacin 4 (16) Other analgesia 8 (32)
Dipyrone 4 (16)
Macrolide Gabapentin 2 (8)
Clarithromycin 2 (8) Morphine 2 (8)
Azithromycin 1 (4) Butorphanol 2 (8)
Fentanyl 1 (4)
Tetracycline Lidocaine CRI 1 (4)
Doxycycline 1 (4)
Other
anti-inflammatory/
anti-endotoxic
Pentoxyfylline 8 (32)
J5 hyperimmune
plasma
2 (8)
Polymixin B 2 (8)
Dexamethasone 2 (8)
Vitamin E 1 (4)
DMSO 1 (4)
Other
Hyperbaric oxygen
treatment
8 (32)
Intravenous ﬂuids 7 (28)
Bronchodilators 3 (12)
Heparin 2 (8)
Diphenhydramine 1 (4)
Stanozolol 1 (4)
R. equi
hyperimmune
plasma
1 (4)
Fenbendazole 1 (4)
Glutathione 1 (4)
Intranasal oxygen 1 (4)
Hetastarch 1 (4)
Furosemide 1 (4)
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was 2 (range, 1–8 doses), and per hemithorax was 1
(range, 1–4 doses) for a total of 55 doses among 25
horses. Seventeen horses received rTPA treatment in 1
hemithorax (12 on the right and 5 on the left) and the
remaining 8 horses received treatments in both hemitho-
races. The dose of rTPA used per hemithorax was
highly variable with a median of 3750 lg (range,
375–20,000 lg). Recombinant tissue plasminogen acti-
vator was diluted in 10 mL–2 L of polyionic solution
for administration and was infused through the existing
thoracic drains or through a teat cannula into a speciﬁc
ﬁbrin loculation, which the clinician desired to break
down. Indwelling tubes were clamped for a median of
24 h (range, 0.5–36 h) to prevent medication from
draining out. Fifteen of 25 horses had the chest lavaged
with 1–20 L polyionic ﬂuids before administration of
rTPA. Two horses received intrapleural amikacin in
combination with rTPA, and 5 horses were treated with
intrapleurally administered antimicrobials (potassium
penicillin, gentamicin, metronidazole, amikacin) at other
times.
Thoracic sonography was performed before rTPA
administration for all doses and within 24 h of
unclamping the tubes after 49 of 55 doses. Thirty two
of 49 (65%) treatments with follow-up sonographic
evaluation resulted in notable improvement. The vol-
ume of drainage immediately upon unclamping the
tubes after rTPA administration was not routinely
recorded, but for the 15 doses for which it was
recorded, the median amount drained was 1.5 L (range,
0–6 L). All horses had sonographic follow-up evalua-
tion after at least 1 dose, but only 20 horses had sono-
graphic follow-up for all doses. Seventeen (17/20, 85%)
of those showed notable decreases in ﬁbrin loculations,
ﬁbrin mat thickness, ﬂuid depth, or some combination
of these within 24 h of at least 1 rTPA treatment.
Complications secondary to pleuropneumonia were
seen in 20 horses (Table 3). Of 3 horses that developed
a pleural abscess, 1 required prolonged drainage
(42 days), another required thoracotomy, and 1 was
euthanized. Although 2 horses developed jugular vein
thrombosis, no evidence of hemorrhagic coagulopathy
was seen.
Eighteen (72%) horses survived and 7 were eutha-
nized. Reasons for euthanasia were severity of disease
and poor response to treatment (4), development of
laminitis (3), and ﬁnancial considerations (3). Excluding
horses euthanized for ﬁnancial reasons, 82% survived.
Ten survivors were racehorses (8 Thoroughbred, 1
Quarter Horse, 1 Standardbred), 4 of which returned to
racing, with 2 winning at least once. Both winners had
a bronchopleural ﬁstula. Five racehorses were retired
without attempt to retrain for racing. Two of the 5
became riding horses and the other 3 were retired to be
broodmares. One racehorse did not race again but was
otherwise lost to follow-up. Of the remaining 8 non-
racehorse survivors, 1 broodmare foaled successfully, 1
competitive western riding horse was retired to pleasure
riding without an attempt to return to previous perfor-
mance level, 1 was euthanized 8 months after discharge
because of orthopedic injury, and 5 were lost to follow-
up.
The median duration of hospitalization was 19 days
(range, 8–210 days) with median hospital charges of
$9800 USD (range, $3743–$30,000). The median total
cost per horse for rTPA was $605 USD (range: $176–
$1201) which represented 1–15% of each horse’s total
hospital charges. The cost per mg of rTPA varied
widely (median $88, range $8–370 USD/mg).
Foul odor of breath, pleural ﬂuid, or both
(OR = 0.052, CI = 0.007–0.38, P = 0.004) but not
anaerobic infection was highly associated with no sono-
graphic improvement after IPFT. Infection with enter-
obacteriaceae was associated with an 83% lower odds
of sonographic response to rTPA treatment (OR = 0.17,
CI = 0.027–0.99, P = 0.05) whereas infection with
Escherichia coli was associated with an 86% lower odds
of sonographic response to rTPA treatment (OR = 0.14,
CI = 0.019–1.07, P = 0.058).
Earlier onset of rTPA treatment during hospitaliza-
tion was associated with increased odds of survival (OR
for ln[day of ﬁrst rTPA dose] = 0.22, P = 0.034, Fig. 1).
There was no association between cumulative rTPA
dosage or number of rTPA doses and any outcome.
There was no association between any other variable
tested and survival. The survival rate for horses treated
with IPFT in this study (72%) was not statistically dif-
ferent from the survival of horses with ﬁbrinous pleural
eﬀusion that did not receive IPFT (62%).1 Horses trea-
ted with IPFT had nonsigniﬁcantly lower rates of pleu-
ral abscessation (12%) and surgical intervention (4%)
compared to 19% and 7.9%, respectively, in horses
with ﬁbrinous pleural eﬀusion that were not treated
with IPFT.1
Discussion
Intrapleural ﬁbrinolytic treatment has been used for
over 60 years in people with variable success. Several
reviews have concluded that IPFT appears to decrease
the requirement for surgical interventions but does not
Table 3. The development of and survival with com-
plications in 25 horses with bacterial pleuropneumonia
that received intrapleural ﬁbrinolytic treatment. The
overall survival rate was 18/25 (72%). Most horses
(80%) developed at least 1 complication. No bleeding
complication was observed
Complication No. horses No. survived
No complication 5 5
Any complication 20 13
Pulmonary abscess 11 9
Laminitis 3 0
Pleural abscess 3 2
Bronchopleural ﬁstula 3 2
Cranial mediastinal
abscess
2 0
Jugular vein thrombosis 2 2
Suspected re-inﬂation
pulmonary edema
1 1
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decrease mortality in adults.8,9 Although early studies in
people identiﬁed improved survival after IPFT,10–12 2 of
the largest randomized, placebo-controlled studies in
adults failed to show a positive eﬀect with IPFT with-
out concurrent intrapleural administration of
DNase.13,14 This discrepancy has been attributed to
wide variation in patient selection, dosage regimens,
and type of ﬁbrinolytic agent used (including urokinase,
streptokinase, alphadornase, and rTPA). Unlike in
adults, in pediatric medicine, the use of IPFT is well
accepted and eﬃcacious.15 These ﬁndings are similar to
the ﬁndings in our study. We found an improved odds
of survival with early rTPA treatment, and a suggestion
that surgical intervention might be decreased, although
statistical power was low in this study and the apparent
reduction in the need for surgical intervention was not
statistically signiﬁcant. Although most horses develop
pleuropneumonia as adults, the disease process in many
ways resembles human pediatric cases more than
human adult cases because, in contrast to adults, horse
and children generally are presented without other
comorbidities.13,16–18
The information provided in this study is primarily
descriptive. Conclusions based on the statistical analysis
provided must be considered in the context of the limi-
tations of the study. An appropriate control population
was not available, which means eﬃcacy of treatment
could not be evaluated directly, both in terms of sono-
graphic improvement and survival after IPFT. In partic-
ular, the sonographic improvement noted after 65% of
IPFT treatments is diﬃcult to interpret because no
appropriate control for the likelihood of sonographic
improvement after 24 h of standard treatment was
available. Sonographic evaluation also is largely subjec-
tive and lacks standardized criteria to determine
improvement. Wide variation in the dosage and timing
of treatment limited the power of comparisons of out-
come by dose. Four major causes of bias in case
selection and dosing were identiﬁed. First, because
IPFT still is regarded as an experimental treatment, for
many clinicians it was reserved only for severely aﬀected
horses that were perceived to have a poor prognosis or
high risk of complications. This suggests a bias toward
a higher mortality rate, which could mask a true beneﬁt
of rTPA treatment and account for the lack of statisti-
cal diﬀerence between survival and complication rates
of horses in this study and the companion study.1 How-
ever, this eﬀect could have been oﬀset by having a sec-
ond concurrent bias toward a population of owners
with suﬃcient funds to invest in optimal care and
longer treatment courses. Third, some of the clinicians
used larger dosages based on a single early case report
describing the use of alteplase in a horse.7 Because the
single case contributors generally were using IPFT in
severely aﬀected horses, there might have been some
bias for higher mortality and complication rates in
horses receiving higher doses. Fourth, due to the cost of
treatment, most clinicians used the fewest number of
doses possible. Therefore, additional doses were more
likely to be given if there was an incomplete or no
response or more severe disease.
Investigation of IPFT has been hampered by a lack
of fundamental studies examining appropriate dosage
regimens both in people and horses. In this study, no
association between dosage of rTPA and outcome could
be identiﬁed either in the short term (sonographic
improvement) or long term (complication rate, sur-
vival). Although this observation could reﬂect a true
lack of eﬀect of treatment at any dosage, this surprising
ﬁnding is likely to be a factor of small sample size,
number of contributing clinicians, and highly variable
treatment regimens. In humans, doses from 2–100 mg
of alteplase have been used with variable success.11
Dwell times have varied from 1 to 24 hours and fre-
quency of administration from 1 to 3 times
daily.10,11,14,19 For rTPA to be eﬀective, endogenous
plasminogen must be available for conversion into plas-
min. It is unknown whether or not larger or more fre-
quent doses are futile because the natural supply of
plasminogen is exhausted. In human and preclinical
rodent studies, 1 of the few consistent aspects of dosing
is the use of repeated administrations, with once or
twice daily administration for 3 days being the most
common approach.9–11,14,19,20 If a standard 3 day dos-
ing regimen were adopted for horses, results might be
better, but several contributing clinicians reported that
their ability to use a higher dose or to repeat dosing
was limited by the owner’s ﬁnancial commitment to
treatment.
The half-life of rTPA in human plasma is only about
6 minutes11, but its half-life in parapneumonic pleural
ﬂuid is unknown. The short plasma half-life, however,
suggests that long dwell times are likely not helpful. In
this study, no association between dwell time and likeli-
hood of sonographic improvement was found after
IPFT. However, in 1 case, a horse had thoracic sonog-
raphy performed after 2 h of dwell time, at which time
no appreciable changes were present, but repeated eval-
uation at 4 h identiﬁed decreased ﬁbrin loculations.
Fig. 1. The survival rate by the day of hospitalization that rTPA
treatment was started for 25 horses with bacterial pleuropneumonia
and ﬁbrinous pleural eﬀusion that were treated with an intrapleural
ﬁbrinolytic agent, rTPA. Treatment was initiated between day 1
and 76 of hospitalization. By logistic regression, the odds of sur-
vival was higher with earlier onset of treatment (P = 0.034).
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This observation suggests either ongoing rTPA activity,
or a posttreatment eﬀect because of the action of acti-
vated plasmin. Because the rTPA-plasminogen complex
generally must be bound to ﬁbrin, earlier opening of
the drains might not result in loss of active plasmin or
eﬃcacy. Some balance must be achieved between ade-
quate dwell time and early enough opening of the
drains that maximal ﬂuid drainage is achieved before
loculations reform. Based on the ﬁndings of this study
and results from human medicine, a dwell time of 4 h is
tentatively recommended until additional investigations
have been completed.
Earlier administration of the ﬁrst rTPA dose was
associated with improved survival in this study. This
observation does not necessarily imply that starting
treatment on the day of admission would be best, as
only 3 horses were treated on the day of admission.
There is some evidence to suggest that rTPA is only
beneﬁcial in the subset of human patients that did not
have resolution of pleural eﬀusion after 24 h of conven-
tional tube drainage. In a series of prospective trials in
people, all patients with purulent or septic pleural ﬂuid
were treated beginning on the day of admission and no
diﬀerence in outcome was seen with IPFT versus pla-
cebo.14 Conversely, in studies in which IPFT was lim-
ited to patients that still had pleural eﬀusion after 24 h
of chest drainage, a positive eﬀect was observed.10,11
A prospective trial using IPFT in horses that have
incomplete resolution of pleural eﬀusion after 24 h of
tube drainage would be beneﬁcial but is not likely to be
feasible given the high costs and relatively low disease
incidence involved.
Despite the apparent survival beneﬁt of early onset of
treatment, the timing of an individual dose relative to
admission to the hospital was not associated with likeli-
hood of sonographic improvement. Information regard-
ing the timing of treatments relative to the development
of loculations was not available and is probably the
most relevant information because some horses do not
have ﬁbrin or loculations on admission to the hospital.1
No evidence of rTPA-associated hemorrhagic coagu-
lopathy such as petechiation, hemoptysis, or bleeding
at venipuncture or chest drain sites was reported.
Coagulation proﬁles were not performed and subclini-
cal prolongations could have been present. In humans,
bleeding complications occur in approximately 7% of
patients treated with IPFT, but patients who had
bleeding complications more often were receiving con-
current anticoagulation treatment or intrapleural
DNase treatment.11,14,20
Pleural ﬁbrin deposition in parapneumonic eﬀusions
has been shown to be caused primarily by increased
expression of plasminogen activator inhibitor-1 (PAI-1),
which causes an imbalance between procoagulant and
ﬁbrinolytic pathways.21 A newer type of rTPA called
tenecteplase was designed to be more resistant to inhibi-
tion by PAI-1 to overcome the high level of inhibi-
tion.22 This product has been used in a single horse in
combination with a DNase with a successful outcome.23
One possible cause of failure of IPFT with TPA
alone in a previous study14 was that the viscosity of
highly cellular pleural ﬂuids prevented adequate drai-
nage even if TPA successfully decreased intrapleural
loculations. Intrapleural DNase administration has been
used to enzymatically digest cellular DNA, thereby
decreasing the viscosity of the empyemic ﬂuid. In the
previous study, the combination of TPA with a DNase
resulted in 77% fewer referrals for surgical intervention
and a shorter hospitalization time, but also a nonsigniﬁ-
cant increase in bleeding complications.14 It is unclear
whether this requirement for DNase treatment is appli-
cable to horses. Chest drains used in horses generally
are larger than those used in human patients (15 Fr or
less), which might decrease the eﬀect of viscosity on
ability to drain the eﬀusion.
In conclusion, there could be a place for IPFT in the
treatment of ﬁbrinous parapneumonic eﬀusions in
horses. No complications associated with rTPA admin-
istration were detected in this study, and it appears to
be safe to use in horses. In this study, the cost of rTPA
treatment was a small percentage of the entire hospital
charges, suggesting it should not be considered cost
prohibitive. A blinded, randomized, placebo-controlled
study would be ideal but is probably unrealistic based
on low case numbers. Therefore, a tentative treatment
protocol is proposed: consider administration of IPFT
if the pleural eﬀusion remains above the level of the
drain or is trapped in ﬁbrin loculations 24 h after the
placement of indwelling chest drains. Tenecteplase could
be used in preference to alteplase, based on better theo-
retical performance in septic eﬀusions.22 If using alte-
plase, 2–10 mg per dose q12–24 h for 3 days, with a
dwell-time of approximately 4 h is a recommended
treatment course.
Footnote
a StataCorp. 2011. Stata Statistical Software: Release 12. College
Station, TX: StataCorp LP. And Rstudio. 2014. RStudio: Inte-
grated development environment for R (Version 0.98.1056) [Com-
puter software]. Boston, MA. Retrieved September 15, 2014.
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